Designer T Cells for Breast Cancer Therapy: Phase I Studies
Abstract
In the present report we describe studies using chimeric immune receptors consisting of an antibody fragment against the CEA tumor antigen joined to signaling portions of the T cell receptor(IgTCR). The antibody fragment confers CEA specificity to the receptor, while the signaling domains transmit T cell activation signals. These receptors allow the T cells (designer T cells) to bypass immune tolerance to CEA and to activate effector functions in a tumor specific manner. We have partially completed a phase I study using IgTCR-modified designer T cells. These studies demonstrate the specific signaling molecules activate specific T cell effector functions in a tumor specific manner. The study will be completed on a continuing no-cost extension with the funds allocated.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2002
- Accession Number
- ADA408881
Entities
People
- Richard P. Junghans
Organizations
- Beth Israel Deaconess Medical Center